NCT07311993 2026-04-14
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Cellectar Biosciences, Inc.
Phase 1 Recruiting
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
Cellectar, Inc